Rapid updates in optimal personalized management of hematologic malignancies have necessitated increased awareness of emerging targets, such as BTK, BCL2, PI3K, and CD20. This has led to the development of novel treatment strategies in second-line and maintenance settings for patients with B-cell lymphomas, including follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL).
The learning objectives of this program are:
This educational activity is directed toward medical oncologists, hematologists, and other oncology health care professionals interested in the latest advances in the treatment of patients with non-Hodgkin lymphoma. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with non-Hodgkin lymphoma are also invited to attend.
Friday, December 10, 2021
Scientific Session: 7:00 PM – 10:00 PM Eastern Time
Live, Virtual Satellite Symposium
Jason Westin, MD, MS, FACP
Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine
Director, Lymphoma Clinical Research Program Section
Chief, Aggressive Lymphoma
The University of Texas MD Anderson Cancer Center